Dendreon

Dendreon to restructure operations, close N.J. plant, cut 600 positions

Wednesday, August 1, 2012 01:24 PM

Biotechnology company Dendreon has announced a strategic restructuring plan designed to accelerate the company's profitability and future growth, which includes re-configuring Dendreon's manufacturing model with the closure of its Morris Plains, N.J. manufacturing facility, restructuring administrative functions and strengthening the company's commercial functions.

More... »

Mymetics ropes in Dendreon vets

Wednesday, April 11, 2012 12:58 PM

Mymetics, a Swiss-based biotech of mucosal and virosomal-based vaccines for infectious diseases, has appointed Grant E. Pickering as president and CEO and Christopher S. Henney as chairman of the board of directors. The changes were made in connection with Mymetics’ efforts to obtain additional financing and to advance the development of its vaccine platform.

More... »

Genesis Biopharma names Bishop executive chairman

Friday, March 23, 2012 03:12 PM

Genesis Biopharma, a biotechnology company developing targeted cancer immunotherapies, appointed Hans E. Bishop executive chairman of the company's board of directors.

More... »

Dendreon appoints three to executive team

Wednesday, March 14, 2012 09:10 AM

Seattle, Wash.-based Dendreon has appointed three new members to its executive team:

More... »

Dendreon announces CEO and chairman succession plan

Wednesday, February 1, 2012 03:41 PM

Dendreon’s board of directors has elected John H. Johnson president and CEO, succeeding Mitchell H. Gold, M.D., who has served as both for nearly a decade.

More... »

Dendreon names Fenton to board of directors

Tuesday, November 8, 2011 10:12 AM

Dendreon has named Dennis M. Fenton to the board of directors, effective November 8, 2011.

More... »

Dendreon to cut 500 jobs

Friday, September 9, 2011 01:42 PM

Dendreon has reported it will cut 500 jobs as it seeks to trim expenses in light of diminished sales expectations for its high-priced Provenge prostate cancer vaccine, according to Reuters.

More... »

Dendreon’s CSO, Dave Urdal, to retire

Tuesday, March 15, 2011 01:43 PM

David Urdal, the scientific entrepreneur who co-founded Dendreon 15 years ago and helped turn it into a pioneer of cancer immunotherapy, is stepping down from his job as chief scientific officer at the Seattle biotech company, according to Xconomy Seattle.

More... »

Phase Forward Appoints First Chief Privacy Officer

Thursday, December 24, 2009 07:40 AM

Phase Forward appointed long-time employee Michael Owings to the new role of chief privacy officer. Owings will oversee all privacy and data protection processes affecting Phase Forward’s customers and employees, and ensure compliance with all relevant regulations. He will also continue his duties as vice president, quality and regulatory compliance—a title he’s held since 2004.

More... »